Department of Preventive Medicine and Environmental Health, Osaka City University Graduate School of Medicine, and Department of Nephrology and Hypertension, Osaka City General Hospital, Osaka, Japan.
Nephrol Dial Transplant. 2012 Jul;27(7):2806-13. doi: 10.1093/ndt/gfs053. Epub 2012 Apr 5.
Indication of tonsillectomy in IgA nephropathy is controversial. The purpose of this study was to examine the efficacy of tonsillectomy on remission and progression of IgA nephropathy.
We conducted a single-center 7-year historical cohort study in 200 patients with biopsy-proven IgA nephropathy. Study outcomes were clinical remission defined as disappearance of urine abnormalities at two consecutive visits, glomerular filtration rate (GFR) decline defined as 30% GFR decrease from baseline and GFR slope during the follow-up.
Seventy of the 200 patients received tonsillectomy. Tonsillectomy was associated with increased incidence of clinical remission (P+0.01, log-rank test) and decreased incidence of GFR decline (P=0.01, log-rank test). After adjustment for age and gender, hazard ratios in tonsillectomy were 3.90 (95% confidence interval 2.46-6.18) for clinical remission and 0.14 (0.02-1.03) for GFR decline. After further adjustment for laboratory (baseline mean arterial pressure, GFR, 24-h proteinuria and hematuria score), histological (mesangial score, segmental sclerosis or adhesion, endocapillary proliferation and interstitial fibrosis) or treatment variables (steroid and renin-angiotensin system inhibitors), similar results were obtained in each model. Even after exclusion of 69 steroid-treated patients, results did not change. GFR slopes in tonsillectomy and non-tonsillectomy groups were 0.60±3.65 and -1.64±2.59 mL/min/1.73 m2/year, respectively. In the multiple regression model, tonsillectomy prevented GFR decline during the follow-up period (regression coefficient 2.00, P=0.01).
Tonsillectomy was associated with a favorable renal outcome of IgA nephropathy in terms of clinical remission and delayed renal deterioration even in non-steroid-treated patients.
扁桃体切除术在 IgA 肾病中的适应证存在争议。本研究旨在观察扁桃体切除术对 IgA 肾病缓解和进展的疗效。
我们对 200 例经活检证实的 IgA 肾病患者进行了一项为期 7 年的单中心历史队列研究。研究结局为临床缓解定义为连续两次就诊时尿异常消失,肾小球滤过率(GFR)下降定义为从基线起 30%的 GFR 下降和随访期间的 GFR 斜率。
200 例患者中有 70 例接受了扁桃体切除术。扁桃体切除术与临床缓解发生率增加(P+0.01,对数秩检验)和 GFR 下降发生率降低(P=0.01,对数秩检验)相关。在校正年龄和性别后,扁桃体切除术的危险比分别为 3.90(95%置信区间 2.46-6.18)用于临床缓解和 0.14(0.02-1.03)用于 GFR 下降。进一步校正实验室(基线平均动脉压、GFR、24 小时蛋白尿和血尿评分)、组织学(系膜评分、节段性硬化或粘连、毛细血管内增殖和间质纤维化)或治疗变量(类固醇和肾素-血管紧张素系统抑制剂)后,在每个模型中均获得了类似的结果。即使排除了 69 例接受类固醇治疗的患者,结果也没有改变。扁桃体切除术和非扁桃体切除术组的 GFR 斜率分别为 0.60±3.65 和-1.64±2.59 mL/min/1.73 m2/年。在多元回归模型中,扁桃体切除术可防止随访期间 GFR 下降(回归系数 2.00,P=0.01)。
即使在未接受类固醇治疗的患者中,扁桃体切除术也与 IgA 肾病的临床缓解和延缓肾功能恶化的有利肾脏结局相关。